FLOATING DRUG DELIVERY SYSTEM: AN OVERVIEW

1. S. S. Hardenia, A. Jain, R. Patel, and A. Kausal.
Floating Drug Delivery Systems: A Review, Asi. J.
Pharm. Life Sci 1 (3): 284-293 (2011).
2. S. H. Shah, J. K. Patel, and N. V. Patel. Stomach
specific drug delivery systems: A review, Int J.
Pharm. Tech Res 1(3): 623-633 (2009).
3. J. Nadigoti, and Shayeda. Floating drug delivery
systems, Int J. Pharm. Sci. Nano Tech 2(3): 595-604
(2009).
4. A. A. Deshpande, N. H. Shah, C. T. Rhodes and W.
Malick. Development of a novel controlled release
Priyanka et al., ARPB, 2014; Vol 4 (III) ISSN 2250-0774
(REVIEW ARTICLE)
740 | P a g e w w w . a r p b . i n f o
system for gastric retention, Pharm. Res. 14: 815-
819 (1997).
5. Y. Kawashinia, T. Niwa, H. Takcuchi, T. Hino, and Y.
Itoh. Hallow microspheres for use as a floating
controlled drug delivery system in the stomach, J.
Pharm. Sci. 81(2): 135-140 (1992).
6. M. Ichikawa, S.Watembl, and V. A. Miyake.
Preparation and in-vivo evaluation of' floating and
sustained release characteristics, J. Pharm. Sci. 80:
l062-1066 (l99l).
7. Y. Sato, Y. Kawaafaima, and H. Takenchi. In vitro and
in vivo evaluation of riboflavin containing
microballoons for floating controlled delivery
system in healthy humans, Int J. Pharm. 275: 75-82
(2004).
8. N. Washington. Investigation into the barrier action
of an alginate gastric reflux suppressant, Liquid
Gaviscon, Drug Inves 2: 23-30 (1987).
9. V. Kamalakkannan, A. Puratchikody, V. V. Prasanth,
and K. Masilamani. Enhancement of drugs
bioavailability by floating drug delivery system – a
review, Int J. Drug Del 3: 558-570 (2011).
10. J. L. Fabrcgas, C. G. Cucala, J. Pous, and R. A. Sites. In
vitro testing of an antacid formulation with
prolonged gastric residence time, Drug Dev. Ind.
Pharm. 20: 1199-1212 (1994).
11. G. Ponchel and J. M. Irache. Specific and non-specific
bioadhesive particulate system for oral delivery to
the gastrointestinal tract, Adv. Drug Del. Rev. 34:
191-219 (1998).
12. H. B. N. Vedha. The recent developments on gastric
floating drug delivery systems: an overview, Int J.
Pharm. Res 2(1): 524-534 (2010).
13. H. Bechgaard and K. Ladefoged. Distribution of
pellets in the gastrointestinal tract: The influence on
transit time exerted by density or diameter of
pellets, J. Pharm Pharmco. 30: 690-692 (1978).
14. S. S. Davis, S. F. Stockwell, M. J. Taylor, J. G. Hardy,
and D. R. Whelley. The effect on density on the
gastric emptying of Single and multiple-unit dosage
form, Pharm. Res. 3: 208-213 (1986).
15. R. Ito, Y. Mchida, T. Sannan and T. Nagai. Magnetic
granules: a novel system for specific drug delivery
to oesophageal mucosa in oral administration, Int J.
Pharm. 61: 109-117 (1990).
16. J. Fujimori, Y. Machida, and T. Nagai. Preparation of
magnetically-responsive tablet and confirmation of
its gastric residence in beagle dogs, STP Pharm. Sci.
4: 425-430 (l994).
17. L. Whitehead, J. H. Collet, J. T. Fell, H. L. Sharma, and
A. M. Smith. Floating dosage forms: an in vivo study
demonstrating prolonged gastric retention, J. Con.
Rel. 55: 3-12 (1998).
18. B. N. Singh and K. H. Kim. Floating drug delivery
system: An approach to the controlled drug delivery
via gastric retention, J. Con. Rel 63: 235-259 (2000).
19. N. Narang. An updated review on: floating drug
delivery system, Int J. Adv. Pharm. 3(1): 1-7 (2011).
20. S. M. Kadam, S. R. Kadam, U. S. Patil, G. N. Ratan, and
V. G. Jamkandi. Review on floating drug delivery
system: An approach to oral controlled drug
delivery via gastric retention, Int J. Res. Ayu. Pharm.
2(6): 1752-1755 (2011).
21. S. D. Pande. Floating drug delivery system: a new
way for oral drug delivery system, Int J. Pharm. Cli.
Sci. 1-13 (2013).
22. S. Gopalakrishnan, and A. Chenthilnathan. Floating
Drug Delivery Systems: A Review, J. Pharm. Sci.
Tech. 3 (2): 548-554 (2011).
23. S. H. Shah, J. K. Patel, and N. V. Patel. Stomach
specific floating drug delivery system: a review, Int
J. Pharm. Tech. Sci. 1(3): 623-633 (2009).
24. S. D. Pande. Floating drug delivery system: a new
way for oral drug delivery system, Int J. Pharm. Cli.
Sci.: 1-13 (2013).
25. S. Baumgartner, J. Kristl, and F. Vrecer. Optimization
of floating matrix tablets and evaluation of their
gastric residence time, Int J. Pharm. 195: 125-135
(2000).
26. S. Gergogiannis, D. M. Rekkas, P. P. Dallos, and N. H.
Chailis. Floating and swelling characteristics of
various excipients used in controlled release
technology, Drug Dev. Ind. Pharm. 19: 1061-1081
(1993).
27. E. A. Klausner, E. Lavy, D. Stepensky, E. Cserepes, M.
Batra, M. Freidman and A. Hoffman. Furosemide
pharmacokinetics and pharmacodynamics
following gastroretentive dosage form
administration to healthy volunteers, J. Con. Rel. 43:
711-720 (2003).
28. B. N. Singh and K. H. Kim. Floating drug delivery
system: An approach to the controlled drug delivery
via gastric retention, J. Con. Rel 63: 235-259 (2000).
29. R. D. Ingale, V. M. Thakare, B. W. Tekade, and V. R.
Patil. Development and evaluation of ranitidine
hydrochloride floating tablet, Int J. Pharm. Sci. Res.
5(1): 269-274 (2014).
30. S. Mohapatra, R. K. Kar, and S. K. Sahoo. Statistical
optimization of intra-gastric floating tablets of
cefixime trihydrate using mixture design, Int J.
Pharm. Sci. Rew. Res. 24(2): 195-201 (2014).
31. R. Shakya, P. Thapa, and R. N. Saha. In vitro and in
vivo evaluation of gastroretentive floating drug
Priyanka et al., ARPB, 2014; Vol 4 (III) ISSN 2250-0774
(REVIEW ARTICLE)
741 | P a g e w w w . a r p b . i n f o
delivery system of ofloxacin, Asi. J. Pharm. Sci. 8:
191-198 (2013).
32. A. Aslani and H. Jahangiri. Formulation,
characterization and physicochemical evaluation of
ranitidine effervescent tablets, Adv. Pharm. Bull.
3(2): 315-322 (2013).
33. A. R. Potu, N. Raja, L. Amreen and N. Raghunandan.
Formulation and evaluation of controlled release
floating tablets of ketorolac tromethamine, J. Drug
Del. Res. 2(2): 7-17 (2013).
34. S. K. Dash, A. S. Khan, R. Thakur, A. Padhan, D. K.
Gupta, and B. C. Behera. Formulation and in-vitro
characterization of floating tablet of enalapril
maleate, Int J. Pharm. Sci Res. 4(1): 486-496 (2013).
35. N. T. Hwisa, B. R. Chandu, P. Katakam and V. Dasari.
Influence of sodium CMC and HPMC on the physical
characteristics of ofloxacin floating matrix tablets,
Bri. J. Pharm. Res. 3(3): 508-522 (2013).
36. N. P. Chotai, B. Y. Acharya, and K. T. Patel.
Formulation and optimization of acyclovir floating
gastroretentive tablets, Int J. Pharm. Sci. 4(4): 113-
131 (2013).
37. V. S. Meka, and S. R. Nali. Statistical design and
evaluation of a propranolol HCl gastric floating
tablet, Acta Pharm. Sini. B2 (1): 60-69 (2012).
38. P. K. Lende, M. S. Junagade, and A. D. Deshmukh.
Formulation optimization and in-vitro evaluation of
floating tablet of stavudine, Amer. J. Pharm. Tech.
Res. 2(5): 723-739 (2012).
39. R. Parthibarajan, N. L. Gowrishankar, M. Rajitha, A.
Vinaykumar, M. Himavanthu, K. Ramesh, M.
Himavanth, and K. Vijaya. Formulation and
evaluation of voriconazole floating tablets, Asi. J.
Pharm. Cli. Res. 5(3): 180-184 (2012).
40. E. K. Patel, and M. Lande. Formulation and
development of floating tablet of highly water
soluble drug using combination of hydrophilic and
hydrophobic polymers, Ame. J. Pharm. Tech. Res.
2(5): (2012).
41. S. D. Chella, S. Vengatesh, and K. Elango.
Formulation and evaluation of floating tablets of
ondansetron hydrochloride, Int J. Drug Dev. Res.
4(4): 265-274 (2012).
42. N. G. Rao, R. Firangi, and K. Patel. Formulation and
evaluation of gastroretentive effervescent floating
drug delivery system of zidovudine, Ame. J. Pharm.
Tech. Res. 2(1): (2012).
43. C. R. Baru, S. Vidyadhara, R. K. V. Rao, P. K. Vanitha
and B. Umashankar. Formulation and evaluation of
ibroprofen floating tablets, Int J. Pharm. Chem. Bio.
Sci. 2(4): 472-481 (2012).
44. A. Kumar and G. P. Mohanta. Formulation and in
vitro evaluation of famotidine floating tablets by
lipid solid dispersion spray drying technique, Int J.
Res. Pharm. Chem. 2(4): 996-1000 (2012).
45. B. K. Gupta, S. S. Sethy, G. Nandi, D. Sarkar, and L. K.
Ghosh. Formulation optimization of a floating
extended release matrix tablet of metformin
hydrochloride, Asi. J. Pharm. Res. 2(4): 714-725
(2012).
46. E. S. Reddy, M. M. Iqbal, S. M. Kazim, S. Asad, and M.
Ibrahim. Formulation and evaluation of sustained
release floating tablets of ciprofloxacin with hepatoprotectant,
Int J. Pharm. App. 3(1): 289-292 (2012).
47. S. K. Chinthala, K. S. Reddy, M. Hadassah, and S.
Sridevi. Formulation and evaluation of
gastroretentive floating tablets of gabapentin using
effervescent technology, Int J. Pharm. Bio. Sci. 3(4):
202-208 (2012).
48. R. Natarajan, N. Kaveri and N. N. R. Rajndran.
Formulation and evaluation of aceclofenac gastro
retentive drug delivery system, Res. J. Pharm. Bio.
Chem. Sci. 2(1): 765-771 (2011).
49. N. S. Sheth and R. B. Mistry. Formulation and
evaluation of floating drug delivery system, Int J.
Pharm. Bio. Sci. 2(1): 571-580 (2011).
50. U. Golla, B. K. Nalla, R. Talla, P. K. Gajam, and S. K.
Voore. Formulation and in vitro evaluation of
gastroretentive drug delivery system of
ciprofloxacin hydrochloride, Pharm. Res. Inv. 2(4):
33-39 (2011).
51. A. Arunachalam, B. S. Rathinaraj, D. Kumaraswamy,
and A. M. Umarunnisha. Design and evaluation of
levofloxacin hemihydrate floating tablets, Int J. Appl.
Bio. Pharm. Tech. 1(2): 260-268 (2010).
52. V. G. Karkhile, R. R. Karmarkar, M. A. Sontakke, S. D.
Badgujar, and L. S. Nemade. Formulation and
evaluation of floating tablets of furosemide, Int J.
Pharm. Res. Dev. 1(12): 1-9 (2010).
53. D. M. Sakarkar, R.V. Kshirsagar and R. M.
Deshbhratar. Studies on formulation and in vitro
evaluation of gastroretentive drug delivery system
of carbamazepine, Int J. Chem. Tech. Res. 2(1):108-
113 (2010).
54. L. S. Danki, A. Sayeed and S. Salger. Design and in
vitro evaluation of gastric floating drug delivery
systems of fenofibrate, Int J. Pharm. Bio. Sci. 1(2): 1-
27 (2010).
55. R. Kaza, E. Usharani, R. Nagaraju, R. Haribabu and P.
V. S. Reddy. Design and Evaluation of Sustained
release Floating tablets for the treatment of Gastric
Ulcers, J. Pharm. Sci. Res. 1(4): 81-87 (2009).
Priyanka et al., ARPB, 2014; Vol 4 (III) ISSN 2250-0774
(REVIEW ARTICLE)
742 | P a g e w w w . a r p b . i n f o
56. A. Pare, S. K. Yadav, and U. K. Patil. Formulation and
evaluation of effervescent floating tablet of
amlodipine besylate, Res. J. Pharm. Tech. 1(4): 526-
530 (2008).
57. T. Tokumura and Y. Machida. Preparation of
amoxicillin intragastric buoyant sustained-release
tablets and the dissolution characteristics, J. Con.
Rel. 110: 581-586 (2006).
58. E. G. Daniel, S. Jaachim, A. C. G. Patrick, V. A. Eberle
and J. Huwyler. Gastroretentive drug formulation
and delivery system and their method of
preparation using functionalized calcium carbonate,
W.O. Patent WO2014057026 A1, 2014.
59. M. Hassan. Gastroretentive drug delivery system
comparising an extruded hydrotable polymer, E. P.
Patent EP1512508 B1, 2014.
60. D. Hunkeler, K. Eichler, and J. Amold.
Gastroretentive drug delivery system for controlled
drug release in the stomach and into the upper
intestine, U. S. Patent US20130315991 A1, 2013.
61. U. D. Kohle and M. G. K. Kulkarni. Use of
pharmaceutical composition for gastroretentive
sustained and pulsatile drug delivery system, W. O.
Patent WO2013051036 A1, 2013.
62. Y. J. Parket. Sustained release preparation using
gastroretentive drug delivery system, W. O. Patent
WO2013162114 A1, 2013.
63. V. Kumar, S. Ahmad and R. B. Singh. A
gastroretentive dosage system and process of
preparation, W. O. Patent WO2013054285 A1,
2013.
64. C. P. Bohtra, S. L. Shrinivasan, K. Raghupati, and M.
S. Basivarao. Gastroretentive drug delivery system
of calcium supplements, W. O. Patent
WO2013114390 A1, 2013.
65. S. Masri, E. Moor, D. Kirmayer, E. Kluev, G. Carni, and
N. Nadar. Zaleplan gastroretentive drug delivery
system, U. S. Patent US20120021051 A1, 2012.
66. N. Nadar, J. Shvetz, E. Moor, K. Kirmayer, E. Kluer, S.
Masri, G. Carni, and Z. Weiss. Baclofen
gastroretentive drug delivery system, U. S. Patent
US20110091542 A1, 2011.
67. N. Nadar, E. Moor, D. Kirmayer, E. Kluer, and G.
Carni. Carbidopa/lipodopa gastroretentive drug
delivery, E. P. Patent EP2276473 A1, 2011.
68. S. Gorukanti, Y. Zu, P. Kotamraj and S. U. Ahmed.
Modified gastroretentive drug delivery system for
amine drugs, W. O. Patent WO2011146611 A1,
2011.
69. Q. Jiang, J. Zheng, W. Yarg, and Q. Liu.
Gastroretentive drug delivery system: preparation,
method and use, U. S. Patent US2011071275 A1,
2011.
70. N. M. Chandvarkar, K. C. Jindal, and R. Malayandi. A
novel gastroretentive delivery of macrolide, W. O.
Patent WO2011125075 A2, 2011.
71. V. Pillay, Y. Choonara, C. Murphy, and S. Moonisami.
Gastroretentive pharmaceutical dosage form, U. S.
Patent US20110182988 A1, 2011.
72. N. Nadar, J. Shuetz, E. Moor, D. Kirmayer, E. Kluev,
and G. Carni. Baclofen gastroretentive drug delivery
system, W. O. Patent WO2010064100 A1, 2010.
73. M. Friedman and D. Kirmayer. Novel gastroretentive
delivery system, W. O. Patent WO2010035273 A2,
2010.
74. K. M. Dudhara, N. B. Dharmadhikari, and V. V. Davas.
Gastric retention controlled drug delivery system,
U. S. Patent US7776345 B2, 2010.
75. S. Welzig, J. R. Burger, B. Kalz, J. Gungl, and K.
Gerdus. Tolperisone controlled release tablet, E. P.
Patent EP2228056 A2, 2010.
76. J. Ogorka, N. J. Kavimandan, J. P. Lakshman, A. S.
Mathan, and A. E. Royce. Extended release
gastroretentive oral drug delivery system of
valsartan, E. P. Patent EP2061438 A1, 2009.
77. V. S. Nande. Gastroretentive drug delivery system,
W. O. Patent WO2009087665 A3, 2009.
78. P. Prinderre. Process for making gastroretentive
dosage forms, E. P. Patent EP2133070 A1, 2009.
79. S. D. Han, S. W. Javg, J. H. Kim, J. Wooler, S. H. Park
and M. H. Yoo. Gastroretentive system containing
solubilized drug for maximizing its therapeutic
effect for gastritis, W. O. Patent WO2009008632 A2,
2009.
80. J. Liao, P. Liu, S. Dinh, B. Singh, S. Majuru, and P. N.
Bhargava. Gastric retention and controlled release
delivery system, E. P. Patent EP1843755 A2, 2007.
81. M. Friedman, A. Hoffman, E. Klausner, and E. Lavy.
Gastroretentive controlled release pharmaceutical
dosage form, E. P. Patent EP1235557 B1, 2005.
82. L. Llium, Heping. Microsphere comprising a drug
containing polymeric rate controlling layer and a
bioadhesive outer layer of cationic polymer;
treatment of helicobactor pylori, U. S. Patent
US6207197 A1, 2001.